Skip to main content
. Author manuscript; available in PMC: 2016 Jul 25.
Published in final edited form as: Nat Immunol. 2016 Jan 25;17(3):277–285. doi: 10.1038/ni.3365

Figure 5. Dysregulation of glycolytic metabolism in Atg7-deficient Treg cells contributes to impaired Treg cell stability.

Figure 5

(a) Measurement of ECAR in Treg cells (from Foxp3CreAtg7+/fl and Foxp3CreAtg7fl/fl mice) stimulated with anti-CD3 and anti-CD28 for 4 h. (b) Ratio of OCR to ECAR of Treg cells (from Foxp3CreAtg7+/fl and Foxp3CreAtg7fl/fl mice) stimulated with anti-CD3 and anti-CD28 for 4 h. (c) Measurement of ECAR in Treg cells (from Foxp3CreAtg7+/fl and Foxp3CreAtg7fl/fl mice) stimulated with anti-CD3 and anti-CD28 for 4 h in the presence of DMSO or rapamycin. (d) Flow cytometry analyzing YFP-Foxp3 expression in divided Treg cells (from Foxp3CreAtg7+/fl and Foxp3CreAtg7fl/fl mice) that were activated in vitro with anti-CD3, anti-CD28, and IL-2 for 96 h in the presence of DMSO or DCA. Numbers above graphs indicate MFI of YFP-Foxp3. NS, not significant (P > 0.05); * P < 0.05 and ** P < 0.001 (two-tail unpaired Student’s t-test in a,b and one-way ANOVA in c). Data are representative of two (a,b), three (c) or four (d) experiments (mean ± s.e.m in a–c).

HHS Vulnerability Disclosure